NCT01932697View on ClinicalTrials.gov

Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

September 4, 2013

Primary Completion Date

October 20, 2016

Study Completion Date

December 28, 2021

Conditions
Human Papillomavirus InfectionStage I Oropharyngeal Squamous Cell CarcinomaStage II Oropharyngeal Squamous Cell CarcinomaStage III Oropharyngeal Squamous Cell CarcinomaStage IVA Oropharyngeal Squamous Cell CarcinomaStage IVB Oropharyngeal Squamous Cell Carcinoma
Interventions
DRUG

Docetaxel

Given IV

RADIATION

Hyperfractionation

Undergo hyperfractionated IMRT

RADIATION

Intensity-Modulated Radiation Therapy

Undergo hyperfractionated IMRT

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (2)

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER